Journey Medical Corporation

NASDAQ:DERM

Drug Manufacturers - Specialty & Generic

Healthcare
$3.69 +0.99%

+$0.06 today

Market cap
$104.15M
Beta
1.10
P/E (TTM)
-17.0
EPS (TTM)
-$0.35
52W Low $4.31High $9.56

Volume 0.25M

Average 0.28M

DERM Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Journey Medical CorporationNASDAQ: DERM

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue grows, but more slowly than its trailing trend

Q1 FY2026 cost of revenue of $7.34M rose 25.4% year over year, behind the +28.6% change in trailing-twelve-month cost of revenue. Sequentially, it rose 12.9% from the prior quarter. Over 3 fiscal years it compounded at -6.5% a year.

Context

  • Cost of revenue amounted to 40.7% of revenue in FY2025, up 3.5 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +25.4% toward the trailing-twelve-month pace of +28.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.34M+12.9% QoQ
Last fiscal yearDec 2025
$25.18M+20.6% YoY
LTMMar 2026
$25.61M+28.6% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.4%——
1 year+20.6%——
3-year CAGR-6.5%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
25.18M USD
Year-over-year change
+20.6%
4-year CAGR
-5.9%

Cost of Revenue vs competitors

How DERM compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +28.6% is the 4th highest of 9, against a peer median of +3.8%.
  • Cost of revenue amounts to 39.6% of revenue for DERM, versus a peer median of 59.0%.
DERM Competitors
Cost of Revenue for DERM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OGIOrganigram Global Inc.LTM Mar 2026CA$176.48M CAD+35.1%—64.4%
OSUROraSure Technologies, Inc.LTM Mar 2026$66.66M USD-28.2%-34.6%59.0%
DERMJourney Medical CorporationLTM Mar 2026$25.61M USD+28.6%-6.5%39.6%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$12.8M USD——721.0%
MDWDMediWound Ltd.LTM Mar 2026$11.64M USD-29.2%+0.9%80.4%
NYXHNyxoah S.A.LTM Mar 2026€8.43M EUR+460.5%+47.5%51.7%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$3.96M USD+31.7%+252.4%7.8%
IVAInventiva S.A.FY2025€2.8M EUR-28.0%+41.1%62.4%
HSDTSolana CompanyLTM Mar 2026$559K USD-3.6%+2.6%5.8%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$238K USD+11.2%-16.1%0.7%
Peer median (excluding DERM) —+3.8%+2.6%59.0%

Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue63.13M73.67M79.18M56.13M61.86M
Cost of Revenue32.08M30.78M26.66M20.88M25.18M
Gross Profit31.05M42.89M52.52M35.26M36.68M
Gross Margin49.2%58.2%66.3%62.8%59.3%
Research & Development16.56M10.94M7.54M9.86M480K
Selling, General & Admin39.83M59.47M43.91M40.2M44.37M
Operating Expenses65.93M70.41M54.59M48.93M44.85M
Depreciation & Amortization2.56M4.37M3.86M3.52M4.35M
EBITDA(32.77M)(23.18M)1.92M(8.4M)(3.33M)
EBITDA Margin-51.9%-31.5%2.4%-15.0%-5.4%
Operating Income(34.88M)(27.52M)(2.07M)(13.68M)(8.17M)
Operating Margin-55.2%-37.4%-2.6%-24.4%-13.2%
Interest Income2K60K322K757K589K
Interest Expense7.03M2.02M1.7M2.7M3.7M
Other Income / Expenses(7.48M)(2.05M)(1.56M)(934K)(3.2M)
Income Before Tax(42.36M)(29.57M)(3.63M)(14.61M)(11.37M)
Pre-Tax Margin-67.1%-40.1%-4.6%-26.0%-18.4%
Income Tax Expense1.63M63K221K61K60K
Net Income(43.99M)(29.63M)(3.85M)(14.67M)(11.43M)
Net Margin-69.7%-40.2%-4.9%-26.1%-18.5%
EPS (Basic)(2.54)(1.69)(0.21)(0.72)(0.47)
EPS (Diluted)(2.54)(1.69)(0.21)(0.72)(0.47)
Weighted Avg Shares17.32M17.53M18.23M20.43M24.5M
Weighted Avg Shares (Diluted)17.32M17.53M18.23M20.43M24.5M

Journey Medical Corporation

NASDAQ:DERM

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.